Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $7.33

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $7.33.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th.

Insider Buying and Selling at Amylyx Pharmaceuticals

In related news, Director Bernhardt G. Zeiher bought 10,000 shares of the stock in a transaction on Thursday, March 20th. The shares were acquired at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $37,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin B. Klee sold 7,471 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the completion of the sale, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,980 shares of company stock worth $252,769 over the last ninety days. 11.70% of the stock is currently owned by company insiders.

Institutional Trading of Amylyx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP purchased a new position in shares of Amylyx Pharmaceuticals in the 4th quarter valued at $793,000. Mackenzie Financial Corp grew its position in shares of Amylyx Pharmaceuticals by 234.9% during the 4th quarter. Mackenzie Financial Corp now owns 111,310 shares of the company’s stock valued at $421,000 after acquiring an additional 78,070 shares during the period. Alpine Global Management LLC purchased a new stake in Amylyx Pharmaceuticals in the 4th quarter worth $45,000. Two Sigma Investments LP increased its stake in Amylyx Pharmaceuticals by 77.4% during the 4th quarter. Two Sigma Investments LP now owns 651,517 shares of the company’s stock worth $2,463,000 after buying an additional 284,280 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at about $249,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Trading Up 13.2 %

NASDAQ AMLX opened at $3.78 on Monday. The company has a 50 day moving average of $3.55 and a 200-day moving average of $4.05. The firm has a market cap of $334.92 million, a price-to-earnings ratio of -0.99 and a beta of -0.51. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. On average, analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.